Seattle Genetics, Inc. Bookmark and Share

ArticleDateSource
Seattle Genetics rare cancer drug sails through accelerated approval--Nature Biotechnology
Seattle Genetics to Present at the J.P. Morgan Healthcare ConferenceJanuary 06, 2014Pharma News - PharmiWeb
Seattle Genetics to Present at the J.P. Morgan Healthcare ConferenceJanuary 06, 2014Biotech News - Business Wire
Seattle Genetics to Present at the J.P. Morgan Healthcare ConferenceJanuary 06, 2014Pharma News - Business Wire
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Phase 2 Clinical Data in Diffuse Large B-cell Lymphoma (DLBCL) at ASH 2013December 10, 2013Biotech News - Business Wire
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Phase 2 Clinical Data in Diffuse Large B-cell Lymphoma (DLBCL) at ASH 2013December 10, 2013Pharma News - Business Wire
Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013November 11, 2013Biotech News - Business Wire
Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013November 11, 2013Pharma News - Business Wire
Seattle Genetics Reports Second Quarter 2013 Financial ResultsJuly 31, 2013Biotech News - Business Wire
Bayer Joins with Seattle Genetics in Antibody-Drug Conjugate DealJune 25, 2013Xconomy Life Sciences
Bayer, Seattle Genetics Launch Up to $520M ADC CollaborationJune 25, 2013Inside Industry - Gen
Seattle Genetics make deal with BayerJune 25, 2013Health News - BizJournals.com
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with BayerJune 25, 2013Pharma News - PharmiWeb
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with BayerJune 25, 2013Biotech News - Business Wire
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with BayerJune 25, 2013Pharma News - Business Wire
Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant LymphomaJune 19, 2013Biotech News - Business Wire
Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant LymphomaJune 19, 2013Pharma News - Business Wire
Seattle Genetics Reports First Quarter 2013 Financial ResultsMay 07, 2013Biotech News - Business Wire
Seattle Genetics Reports First Quarter 2013 Financial ResultsMay 07, 2013Pharma News - Business Wire
Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACRApril 09, 2013Biotech News - Business Wire
Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACRApril 09, 2013Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013January 29, 2013Pharma News - PharmiWeb
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013January 29, 2013Biotech News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013January 29, 2013Pharma News - Business Wire
Seattle Genetics gets undisclosed milestone paymentsOctober 09, 2012Health News - BizJournals.com
Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II DevelopmentOctober 09, 2012Pharma News - Business Wire
Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell LymphomaOctober 01, 2012Pharma News - Business Wire
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin LymphomaSeptember 25, 2012Pharma News - Business Wire
Seattle Genetics Announces ADCETRIS® Receives Positive CHMP Opinion for Conditional Approval in European UnionJuly 20, 2012Pharma News - Business Wire
Cramer Interviews Seattle Genetics CEOJune 05, 2012Health News - CNBC
Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for ReviewMay 23, 2012Pharma News - Business Wire
Seattle Genetics Follows the Science, Taking on Rare Lymphoma No. 3May 23, 2012Xconomy Life Sciences
Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual MeetingMay 16, 2012Pharma News - Business Wire
Seattle Genetics to Present at Bank of America Merrill Lynch Health Care ConferenceMay 11, 2012Pharma News - Business Wire
Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell LymphomaMay 10, 2012Pharma News - Business Wire
Seattle Genetics pares Q1 loss, stock slipsMay 09, 2012Health News - BizJournals.com
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B FutureMay 08, 2012Xconomy Life Sciences
Seattle Genetics Reports First Quarter 2012 Financial ResultsMay 08, 2012Pharma News - Business Wire
Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell LymphomaMay 07, 2012Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2012 Financial Results on May 8, 2012April 24, 2012Pharma News - Business Wire
Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACRApril 03, 2012Pharma News - Business Wire
Seattle Genetics to Present at Needham Healthcare ConferenceMarch 29, 2012Pharma News - Business Wire
Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical OncologyMarch 26, 2012Pharma News - Business Wire
Seattle Genetics Appoints Dr. Nancy Simonian to Board of DirectorsMarch 21, 2012Pharma News - Business Wire
Seattle Genetics Digs Deeper Into the Proverbial HaystackMarch 13, 2012Xconomy Life Sciences
Seattle Genetics Digs Into the Haystack, Looking for More than One NeedleMarch 13, 2012Xconomy Life Sciences
Seattle Genetics Found Its Needle in the Haystack, Sparking Big Push For MoreMarch 13, 2012Xconomy Life Sciences
Seattle Genetics Gets New Commercial Boss for Early Days of AdcetrisFebruary 23, 2012Xconomy Life Sciences
Seattle Genetics Gets New Commercial Boss for Early Days of AdcetrisFebruary 23, 2012Xconomy Life Sciences
Seattle Genetics Provides Update on Commercial LeadershipFebruary 23, 2012Pharma News - Business Wire
Seattle Genetics 2011 net loss more than double over 2010, but Q4 result improvesFebruary 14, 2012Health News - BizJournals.com
Seattle Genetics Reports Fourth Quarter and Year 2011 Financial ResultsFebruary 13, 2012Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2011 Financial Results on February 13, 2012February 01, 2012Pharma News - Business Wire
Seattle Genetics Announces Data from ADCETRIS™ in Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaJanuary 26, 2012Pharma News - Business Wire
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell LymphomasJanuary 26, 2012Pharma News - Business Wire
Seattle Genetics has the Lowest Free Cash Flow Per Share in the Biotechnology Industry (SGEN, ARIA, ORCH, RGEN, OREX)January 18, 2012Biotechnology - Moreover
Seattle Genetics ([[SGEN -4.8%) and Takeda Pharmaceutical ([[TKPYY.PK -1.00%) dip after the FDA says it's seen three cases of serious brain infection among patients being treated with their jointly-produced lymphoma drug Adcetris, and strengthened theJanuary 13, 2012Pharmaceutical - Moreover
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference (BIZ)January 04, 2012Biotechnology - Moreover
Seattle Genetics is Among the Companies in the Biotechnology Industry With the Lowest Free Cash Flow Per Share (SGEN, ARIA, ORCH, RGEN, OREX)December 19, 2011Biotechnology - Moreover
Seattle Genetics And Takeda Pharmaceutical Company Limited's Millennium Report Data From Phase I Trial Of ADCETRIS (Brentuximab Vedotin) In Front-line Hodgkin LymphomaDecember 14, 2011Pharmaceutical - Moreover
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS(TM) (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting - Phase III Front-line Trial Planned in Advanced Stage Hodgkin Lymphoma Patients -December 13, 2011Pharmaceutical - Moreover
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual MeetingDecember 13, 2011Pharma News - Business Wire
Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS™ (Brentuximab Vedotin) at ASH Annual MeetingDecember 12, 2011Pharma News - Business Wire
Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS™ (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual MeetingDecember 12, 2011Pharma News - Business Wire
Seattle Genetics to Present at Upcoming Investor ConferenceDecember 07, 2011Pharma News - Business Wire
Seattle Genetics Sees Case of PML, Causing Market TwitchDecember 01, 2011Xconomy Life Sciences
Seattle Genetics Sees 2nd Case of PML, Causing Market to Twitch, then RelaxDecember 01, 2011Xconomy Life Sciences
Seattle Genetics Falls 1.99% on Heavy Volume: Watch For Potential Rebound (SGEN)November 21, 2011Biotechnology - Moreover
Look for Shares of Seattle Genetics to Potentially Rebound after Yesterday's 1.94% Sell Off (SGEN)November 15, 2011Biotechnology - Moreover
Seattle Genetics and Millennium Announce Presentation of ADCETRIS™ Data at American Society of Hematology Annual MeetingNovember 08, 2011Pharma News - Business Wire
Seattle Genetics had the Lowest Relative Performance in the Biotechnology ...November 08, 2011Biotechnology - Moreover
SEATTLE GENETICS, INC.: Seattle Genetics to Present at Two Upcoming Investor ConferencesNovember 07, 2011Biotechnology - Moreover
SEATTLE GENETICS, INC. : Seattle Genetics to Present at Two Upcoming Investor ConferencesNovember 07, 2011Biotechnology - Moreover
Seattle Genetics beats Wall Street predictions for new cancer drugNovember 04, 2011Health News - BizJournals.com
Seattle Genetics Reports Third Quarter 2011 Financial ResultsNovember 03, 2011Pharma News - Business Wire
Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug DebutNovember 03, 2011Xconomy Life Sciences
Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management PromotionOctober 26, 2011Pharma News - Business Wire
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Lymphoma MalignanciesOctober 25, 2011Pharma News - Business Wire
Analyst: Seattle Genetics should outperform forecastsOctober 21, 2011Health News - BizJournals.com
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug RolloutOctober 20, 2011Xconomy Life Sciences
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2011 Financial Results on November 3, 2011October 20, 2011Pharma News - Business Wire
Zishen Fan sentenced to 18 months in Seattle Genetics insider trading caseOctober 08, 2011Health News - BizJournals.com
Resumen: Millennium y Seattle Genetics presentan datos clínicos sobre ADCETRISTM (Brentuximab Vedotin) en pacientes pediátricos en reunión anual de la EMCCSeptember 26, 2011Pharma News - Business Wire
Millennium et Seattle Genetics présentent, à l’occasion de la réunion annuelle de l’EMCC, des données cliniques concernant l’utilisation d’ADCETRIS™ (Brentuximab Vedotin) chez les patients pédiatriquesSeptember 24, 2011Pharma News - Business Wire
Millennium und Seattle Genetics legen auf der EMCC-Jahrestagung klinische Daten zu ADCETRIS™ (Brentuximab Vedotin) bei pädiatrischen Patienten vorSeptember 24, 2011Pharma News - Business Wire
Riassunto: Millennium e Seattle Genetics presentano dati clinici su ADCETRIS™ (brentuximab vedotin) nei pazienti pediatrici all'assemblea annuale dell'EMCCSeptember 24, 2011Pharma News - Business Wire
Samenvatting: Millennium en Seattle Genetics presenteren klinische gegevens over ADCETRIS (brentuximab vedotin) bij pediatrische patiënten op jaarlijkse bijeenkomst EMCCSeptember 24, 2011Pharma News - Business Wire
Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual MeetingSeptember 24, 2011Pharma News - Business Wire
Seattle Genetics and OBT Establish Cancer Antibody-Drug Conjugate CollaborationSeptember 13, 2011Inside Industry - Gen
Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer -Companies to combine proprietary technologies to generate novel ADC product candidates-September 13, 2011Biotechnology - Moreover
Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for CancerSeptember 13, 2011Pharma News - Business Wire
Seattle Genetics to Present at Two Upcoming Investor ConferencesSeptember 08, 2011Pharma News - Business Wire
Seattle Genetics cancer drug price may top $100,000 (Reuters) August 22, 2011Yahoo Biotech News
Seattle Genetics Reports Second Quarter 2011 Financial ResultsAugust 04, 2011Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2011 Financial Results on August 4, 2011July 26, 2011Pharma News - Business Wire
Seattle Genetics stock drops; CEO still confidentJuly 15, 2011Health News - BizJournals.com
Seattle Genetics wins FDA panel's OKJuly 14, 2011Health News - BizJournals.com
Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS™ for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCLJuly 14, 2011Pharma News - Business Wire
FDA panel backs Seattle Genetics drug for lymphomaJuly 14, 2011Health News - CNBC
FDA panel backs Seattle Genetics drug for lymphoma (Reuters) July 14, 2011Yahoo Biotech News
Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA PanelJuly 14, 2011Xconomy Life Sciences
UPDATED: Seattle Genetics lymphoma drug gets FDA panel nod July 14, 2011FierceBiotech
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA PanelJuly 14, 2011Xconomy Life Sciences
Seattle Genetics Wins Unanimous FDA Panel Recommendation for Hodgkin’s DiseaseJuly 14, 2011Xconomy Life Sciences
Seattle Genetics drug gets FDA panel nod for Hodgkin patients July 14, 2011FierceBiotech
Trading in Seattle Genetics shares haltedJuly 14, 2011Health News - BizJournals.com
Trading of Seattle Genetics Common Stock HaltedJuly 14, 2011Pharma News - Business Wire
Guilty plea in Seattle Genetics insider trading caseJuly 12, 2011Health News - BizJournals.com
Trial size may limit use of Seattle Genetics drug (Reuters) July 12, 2011Yahoo Biotech News
FDA eyes trial size for Seattle Genetics cancer drugJuly 12, 2011Health News - CNBC
Seattle Genetics takes step closer with FDA review of lymphoma drugJuly 12, 2011FierceBiotech
FDA eyes trial size for Seattle Genetics cancer drug (Reuters) July 12, 2011Yahoo Biotech News
Seattle Genetics Announced It Will Recieve A $5M Milestone PJune 28, 2011Pharmaceutical - Moreover
Seattle Genetics gets $5M milestone paymentJune 27, 2011Health News - BizJournals.com
Seattle Genetics (SGEN) to Receive Multi-Million Milestone Under ADCETRISTM CollaborationJune 27, 2011Pharmaceutical - Moreover
Seattle Genetics Achieves Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAAJune 27, 2011Pharma News - Business Wire
Seattle Genetics promotes Eric Dobmeier to COOJune 17, 2011Health News - BizJournals.com
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating OfficerJune 17, 2011Pharma News - Business Wire
FDA committee to review Seattle Genetics cancer drug applications in JulyJune 16, 2011Health News - BizJournals.com
Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCLJune 16, 2011FDA News - Business Wire
Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Clinical Data at International Conference on Malignant LymphomaJune 15, 2011Pharma News - Business Wire
Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual MeetingJune 11, 2011Pharma News - Business Wire
Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual MeetingJune 10, 2011FDA News - Business Wire
Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing CollaborationJune 09, 2011Pharma News - Business Wire
Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual MeetingJune 06, 2011Pharma News - Business Wire
Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual MeetingJune 06, 2011Pharma News - Business Wire
Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology AssociationMay 27, 2011Pharma News - Business Wire
Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical Data at the American Society of Clinical Oncology Annual MeetingMay 19, 2011Pharma News - Business Wire
Seattle Genetics reports 1Q loss on revenue dipMay 06, 2011Health News - CNBC
Seattle Genetics posts loss for Q1May 06, 2011Health News - BizJournals.com
Seattle Genetics Reports First Quarter 2011 Financial ResultsMay 05, 2011Pharma News - Business Wire
Seattle Genetics shares rise in heavy tradingMay 04, 2011Health News - BizJournals.com
Seattle Genetics: FDA reviewing cancer drug applicationsMay 02, 2011Health News - BizJournals.com
Seattle Genetics says FDA is reviewing cancer drugMay 02, 2011Health News - CNBC
Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Priority Review for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCLMay 02, 2011FDA News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2011 Financial Results on May 5, 2011April 26, 2011Pharma News - Business Wire
Genmab, Seattle Genetics Expand ADC PactApril 19, 2011Contract Pharma
Seattle Genetics and Genmab expand collaborationApril 19, 2011Health News - CNBC
Genmab and Seattle Genetics Expand Antibody-Drug Conjugate CollaborationApril 19, 2011Pharma News - Business Wire
Seattle Genetics Appoints Vice President, Corporate Development and Announces Management PromotionApril 18, 2011Pharma News - Business Wire
Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical DevelopmentApril 13, 2011Pharma News - Business Wire
Seattle Genetics Reports Brentuximab Vedotin (SGN-35) Data at EBMT Annual MeetingApril 06, 2011Pharma News - Business Wire
Seattle Genetics Highlights ADC Technology Research at AACRApril 05, 2011Pharma News - Business Wire
Lightning Round: Baidu, Accuride, Seattle Genetics and MoreMarch 25, 2011Biotechnology - Moreover
Seattle Genetics Enters Antibody-Drug Conjugate Collaboration with AbbottMarch 25, 2011Biotechnology - Moreover
Seattle Genetics enters into ADC collaboration agreement with AbbottMarch 23, 2011Pharmaceutical - Moreover
Seattle Genetics in $8M deal with AbbottMarch 22, 2011Health News - BizJournals.com
Seattle Genetics strikes again with $208M ADC deal with AbbottMarch 22, 2011FierceBiotech
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with AbbottMarch 22, 2011Pharma News - Business Wire
Seattle Genetics gets fee in Takeda contractMarch 15, 2011Pharmaceutical - Moreover
Seattle Genetics gets fee for Millennium collaborationMarch 15, 2011Health News - BizJournals.com
Seattle Genetics and Millennium Expand Antibody-Drug Conjugate CollaborationMarch 15, 2011Pharma News - Business Wire
Seattle Genetics to Present at Upcoming Investor Conferences (BIZ)March 03, 2011Biotechnology - Moreover
Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCLMarch 01, 2011Pharma News - Business Wire
Seattle Genetics seeks tumor drug nodFebruary 28, 2011Health News - BizJournals.com
Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCLFebruary 28, 2011FDA News - Business Wire
Seattle Genetics Announces Exercise of Over-Allotment OptionFebruary 03, 2011Pharma News - Business Wire
Seattle Genetics needs fundsFebruary 03, 2011Biotechnology - Moreover
Seattle Genetics Reloads, Uptake Ups and Leaves, PhysioSonics Raises Cash, & More Seattle-Area Life Sciences NewsFebruary 03, 2011Xconomy Life Sciences
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2010 Financial Results on February 8, 2011February 02, 2011Pharma News - Business Wire
Seattle Genetics offering $155 million in stockFebruary 02, 2011Health News - CNBC
Seattle Genetics raises $155M; Chelsea splits trial for Northera;February 02, 2011FierceBiotech
Seattle Genetics tries to raise $155MFebruary 02, 2011Health News - BizJournals.com
Seattle Genetics Reloads Cash Reserves With $155M, On Cusp of Selling First DrugFebruary 02, 2011Xconomy Life Sciences
Seattle Genetics Prices Public Offering of Common StockFebruary 02, 2011Pharma News - Business Wire
Seattle Genetics plans public stock offeringFebruary 01, 2011Health News - CNBC
Seattle Genetics Announces Proposed Public Offering of Common StockFebruary 01, 2011Pharma News - Business Wire
Seattle Genetics Manager Accused of Insider Trading, Bristol Stays in Seattle, Amgen Buys BioVex, & More Seattle-Area Life Sciences NewsJanuary 27, 2011Xconomy Life Sciences
SEC Accuses Seattle Genetics Employee of Insider TradingJanuary 21, 2011Xconomy Life Sciences
Seattle Genetics Gets Some Love on National TV, as Cancer Drug Nears MarketJanuary 14, 2011Xconomy Life Sciences
Seattle Genetics Rises On CEO's Appearance On CNBC (SGEN)January 11, 2011Biotechnology - Moreover
Seattle Genetics to Present at J.P. Morgan Healthcare ConferenceJanuary 10, 2011Biotechnology - Moreover
Seattle Genetics announces Pfizer collaborationJanuary 06, 2011Health News - CNBC
Seattle Genetics Gets $8M From PfizerJanuary 06, 2011Xconomy Life Sciences
Seattle Genetics scores $208M Pfizer pact for ADC techJanuary 06, 2011FierceBiotech
Seattle Genetics Joins With Pfizer On Cancer Drug TechnologyJanuary 06, 2011Health News - Fox Business
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with PfizerJanuary 06, 2011Pharma News - Business Wire
Seattle Genetics Announces Webcast of Presentation at J.P. Morgan Healthcare ConferenceJanuary 04, 2011Pharma News - Business Wire
Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFESTDecember 13, 2010Pharma News - Business Wire
Seattle Genetics and Millennium Report Positive Data from Phase II Trial of BrentuximabDecember 08, 2010Pharmaceutical - Moreover
Seattle Genetics `Guided Missile' Drug Blasts Rare Lymphoma in New StudyDecember 08, 2010Pharmaceutical - Moreover
Seattle Genetics â??Guided Missileâ?? Blasts Rare LymphomaDecember 07, 2010Pharmaceutical - Moreover
Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trialDecember 07, 2010Pharmaceutical - Moreover
Seattle Genetics (SGEN) and Millennium Announce Positive Phase II SGN-35 Data inDecember 07, 2010Pharmaceutical - Moreover
Seattle Genetics ($SGEN) delivers second round of stellar SGN-35 data December 07, 2010FierceBiotech
Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual MeetingDecember 07, 2010Pharma News - Business Wire
Seattle Genetics delivers second round of stellar SGN-35 data December 07, 2010FierceBiotech
Study: Seattle Genetics and Takeda's drug leads to lymphoma remissionDecember 06, 2010Pharmaceutical - Moreover
Seattle Genetics ($SGEN) plots FDA app on promising PhIII cancer dataDecember 06, 2010FierceBiotech
Seattle Genetics ($SGEN) unveils pivotal cancer data, plans for FDA appDecember 06, 2010FierceBiotech
Seattle Genetics to submit lymphoma drug to FDA (Reuters) December 06, 2010Yahoo Biotech News
Seattle Genetics e Millennium presentano al Meeting annuale ASH i dati positivi dallo studio pilota di Brentuximab Vedotin (SGN-35) nel linfoma di Hodgkin recidivante o refrattarioDecember 05, 2010Marketwire - Pharma and Biotech
Seattle Genetics et Millennium Report prsentent lors du congrs annuel de l'ASH des donnes positives pour l'essai pivot valuant le brentuximab vedotin (SGN-35) chez les patients souffrant d'un lymphome de Hodgkin rcidivant ou rfractaireDecember 05, 2010Marketwire - Pharma and Biotech
Seattle Genetics y Millennium presentan datos positivos del ensayo fundamental con brentuximab vedotina (SGN-35) para el linfoma hodgkiniano recidivante o refractario en la Reunin Anual de la ASHDecember 05, 2010Marketwire - Pharma and Biotech
Seattle Genetics und Millennium geben auf der ASH-Jahrestagung positive Ergebnisse der Pivotalstudie zu Brentuximab Vedotin (SGN-35) beim rezidivierten oder refraktren Hodgkin-Lymphom bekanntDecember 05, 2010Marketwire - Pharma and Biotech
Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual MeetingDecember 05, 2010Pharma News - Business Wire
Remission rate 34 pct for Seattle Genetics drug (Reuters) December 05, 2010Yahoo Biotech News
Seattle Genetics Leads Roche in Race to Develop Cancer ComboDecember 02, 2010Pharmaceutical - Moreover
Seattle Genetics Leads Roche in Cancer Combo RaceDecember 01, 2010Pharmaceutical - Moreover
Seattle Genetics announces management changesDecember 01, 2010Biotechnology - Moreover
Seattle Genetics ($SGEN) angling for the lead in combo cancer drug raceDecember 01, 2010FierceBiotech
Seattle Genetics Announces Additions to Commercial Leadership TeamNovember 30, 2010Pharma News - Business Wire
Seattle Genetics to Present at JMP Securities Healthcare Focus ConferenceNovember 29, 2010Biotechnology - Moreover
Seattle Genetics to Present at Piper Jaffray Health Care ConferenceNovember 29, 2010Pharma News - Business Wire
Seattle Genetics: Stock on the Move Lower, Down 1% (SGEN)November 12, 2010Biotechnology - Moreover
Seattle Genetics and Millennium to Present Brentuximab Vedotin Clinical DataNovember 08, 2010Pharmaceutical - Moreover
Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at American Society of Hematology Annual MeetingNovember 08, 2010Pharma News - Business Wire
Seattle Genetics Reports Third Quarter 2010 Financial ResultsNovember 01, 2010Pharma News - Business Wire
Compugen, Seattle Genetics sign cancer drug dealOctober 29, 2010Health News - CNBC
Seattle Genetics to Present at Oppenheimer Healthcare ConferenceOctober 29, 2010Pharma News - Business Wire
Seattle Genetics and Millennium to Highlight Brentuximab Vedotin (SGN-35) at the International Symposium on Hodgkin LymphomaOctober 25, 2010Biotech News - Business Wire
Seattle Genetics Schedules Conference Call and Webcast for 3Q 2010 Financial ResultsOctober 24, 2010Biotechnology - Moreover
Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate CancerOctober 20, 2010Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 2010October 19, 2010Pharma News - Business Wire
Seattle Genetics and Takeda's lymphoma drug performs well in studiesOctober 14, 2010Pharmaceutical - Moreover
Seattle Genetics Nails 2nd Trial, Bristol Clinches Zymo Buyout, Halosource Goes Public, & More Seattle-Area Life Sciences NewsOctober 14, 2010Xconomy Life Sciences
Seattle Genetics and Takeda's lymphoma drug performs well in studyOctober 12, 2010Pharmaceutical - Moreover
Seattle Genetics says cancer drug met study goalOctober 11, 2010Health News - CNBC
Seattle Genetics says lymphoma drug test goes wellOctober 11, 2010Health News - BizJournals.com
Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or Refractory ALCLOctober 11, 2010Pharma News - Business Wire
Seattle Genetics Reports Preliminary Data from Phase I Clinical Trial of SGN-75October 11, 2010Pharma News - Business Wire
Seattle Genetics to Present SGN-75 Clinical Data at the European Society for Medical Oncology (ESMO) CongressOctober 04, 2010Pharma News - Business Wire
Study shows efficacy of Seattle Genetics and Takeda's cancer drugSeptember 28, 2010Pharmaceutical - Moreover
Seattle Genetics cancer drug meets study goalSeptember 27, 2010Health News - CNBC
Seattle Genetics reports positive lymphoma drug test resultsSeptember 27, 2010Health News - BizJournals.com
Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin LymphomaSeptember 27, 2010FDA News - Business Wire
Seattle Genetics to release lymphoma data MondaySeptember 24, 2010Biotechnology - Moreover
Seattle Genetics to release lymphoma trial dataSeptember 24, 2010Health News - BizJournals.com
Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal Hodgkin Lymphoma Clinical TrialSeptember 24, 2010Pharma News - Business Wire
Seattle Genetics Snags Genmab DealSeptember 14, 2010Xconomy Life Sciences
Genmab, Seattle Genetics ink cancer research dealSeptember 14, 2010FierceBiotech
Genmab and Seattle Genetics Enter into Antibody-Drug Conjugate Research CollaborationSeptember 14, 2010Pharma News - Business Wire
Genmab, Seattle Genetics Enter ADC AllianceSeptember 14, 2010Contract Pharma
Seattle Genetics and Genmab in cancer drug dealSeptember 14, 2010Health News - CNBC
Seattle Genetics leukemia drug fails studySeptember 13, 2010Health News - CNBC
Seattle Genetics leukemia drug fails in testSeptember 13, 2010Health News - BizJournals.com
Seattle Genetics will shelve AML drug after PhIIb failureSeptember 13, 2010FierceBiotech
Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary EndpointSeptember 13, 2010Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line...September 10, 2010Biotechnology - Moreover
Seattle Genetics to unveil leukemia data on MondaySeptember 10, 2010Biotechnology - Moreover
Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line Data from Lintuzumab (SGN-33) PhaSeptember 10, 2010Biotechnology - Moreover
Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line Data from Lintuzumab (SGN-33) Phase IIb Clinical TrialSeptember 10, 2010Pharma News - Business Wire
Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of AstellasSeptember 02, 2010Pharma News - Business Wire
Seattle Genetics preps for busy fallAugust 06, 2010FierceBiotech
Dendreon Shows Provenge Demand, Seattle Genetics Inks Big Deal, Corey Gets Top Hutch Job, & More Seattle-Area Life Sciences NewsAugust 05, 2010Xconomy Life Sciences
Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth ConferenceAugust 04, 2010Pharma News - Business Wire
Genentech pays $12M to expand Seattle Genetics pactAugust 03, 2010Health News - BizJournals.com
Seattle Genetics scores $900M cancer pact with GenentechAugust 03, 2010FierceBiotech
Seattle Genetics gets $12M in expanded Genentech dealAugust 03, 2010Health News - BizJournals.com
Genentech Agrees to Pay Seattle Genetics Up to $900M for “Empowered Antibodies”August 03, 2010Xconomy Life Sciences
Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with GenentechAugust 03, 2010Biotech News - Business Wire
Seattle Genetics trims Q2 lossJuly 27, 2010Health News - BizJournals.com
Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline ProgressJuly 27, 2010Biotech News - Business Wire
Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic CancerJuly 20, 2010Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2010 Financial Results on July 27, 2010July 19, 2010Pharma News - Business Wire
Seattle Genetics Shows Re-Treatment ActionJune 05, 2010Xconomy Life Sciences
Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in LymphomaJune 05, 2010Pharma News - Business Wire
Seattle Genetics Announces Webcast Presentations at Upcoming Investor ConferencesJune 02, 2010Pharma News - Business Wire
Seattle Genetics Grows Up Fast, Valocor Seeks to Fight Acne, Cell Therapeutics Nabs $21M & More Seattle-Area Life Sciences NewsMay 27, 2010Xconomy Life Sciences
Seattle Genetics Names Vice President, Sales and Announces Management PromotionMay 24, 2010Pharma News - Business Wire
Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL TrialMay 24, 2010Pharma News - Business Wire
Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at the American Society of Clinical Oncology Annual MeetingMay 21, 2010Pharma News - Business Wire
Seattle Genetics Q1 Revenues UpApril 28, 2010Biotechnology - Moreover
Seattle Genetics sees 1Q profit on partnershipApril 27, 2010Health News - CNBC
Seattle Genetics reports Q1 net income of $11.5MApril 27, 2010Health News - BizJournals.com
Seattle Genetics Reports First Quarter 2010 Financial ResultsApril 27, 2010Pharma News - Business Wire
Seattle Genetics Highlights ADC and SEA Technologies at AACRApril 21, 2010Pharma News - Business Wire
Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACRApril 21, 2010Pharma News - Business Wire
Seattle Genetics Gets $9.5M From GenentechApril 21, 2010Biotechnology - Moreover
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2010 Financial Results on April 27, 2010April 20, 2010Pharma News - Business Wire
Seattle Genetics gets $9.5M payment from RocheApril 20, 2010Health News - CNBC
Seattle Genetics in $9.5M deal with GenentechApril 20, 2010Health News - BizJournals.com
Seattle Genetics Nabs $9.5MApril 20, 2010Xconomy Life Sciences
Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate CollaborationApril 20, 2010Pharma News - Business Wire
Seattle Genetics Inc starts phase III AETHERA trial of brentuximab vedotin for post-transplant Hodgkin lymphomaApril 08, 2010Biotechnology - Moreover
Seattle Genetics Expands An...March 16, 2010Biotechnology - Moreover
Seattle Genetics to Present at Upcoming Investor Conferences - Zi...March 12, 2010Biotechnology - Moreover
Seattle Genetics Adds Patent to 2025March 11, 2010Xconomy Life Sciences
Seattle Genetics Expands Antibody-Drug Conjugate Patent PortfolioMarch 11, 2010Pharma News - Business Wire
Shares of Seattle Genetics Get a Boost, Up 1.1% (SGEN)March 08, 2010Biotechnology - Moreover
Seattle Genetics obtains milestone under collaboration with GenentechMarch 04, 2010Biotechnology - Moreover
Seattle Genetics Reaches Genentech MilestoneMarch 03, 2010Contract Pharma
Seattle Genetics Gets Roche CashMarch 03, 2010Xconomy Life Sciences
Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with GenentechMarch 03, 2010Pharma News - Business Wire
Seattle Genetics to Present at Upcoming Investor ConferencesFebruary 25, 2010Pharma News - Business Wire
Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial OutlookFebruary 09, 2010Pharma News - Business Wire
Seattle Genetics Starts Lymphoma TrialFebruary 03, 2010Xconomy Life Sciences
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin LymphomaFebruary 03, 2010Pharma News - Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010February 02, 2010Pharma News - Business Wire
Accelerator Slowed Down, Inside the Latest Seattle Genetics Deal, Ekos Finds New Use, & More Seattle-Area Life Sciences NewsJanuary 28, 2010Xconomy Life Sciences
Seattle Genetics raises $135.99 million through public offering of common stockJanuary 22, 2010Biotechnology - Moreover
Alder Rises from Ashes, Seattle Genetics Gets Empowered, ZymoGenetics Nets $79M & More Seattle-Area Life Sciences NewsJanuary 07, 2010Xconomy Life Sciences
Seattle Genetics Maps Out a Future With Antibody Drugs That Are “Empowered”January 06, 2010Xconomy Life Sciences
Seattle Genetics to Present at the J.P. Morgan Healthcare ConferenceJanuary 05, 2010Pharma News - Business Wire
GSK, Seattle Genetics in ADC PactDecember 22, 2009Contract Pharma
Seattle Genetics Receives $12M Up Front in Deal with GSKDecember 21, 2009GEN News Highlights
Seattle Genetics Bags $12M From GSKDecember 21, 2009Xconomy Life Sciences
On a roll, Seattle Genetics inks $1.1B in new deals December 21, 2009FierceBiotech
Dendreon Nails Down $409M, Stewart Parker Gets Itch to Return, Seattle Genetics Finds New Partner, & More Seattle-Area Life Sciences NewsDecember 17, 2009Xconomy Life Sciences
Seattle Genetics signs deal worth up to $365MDecember 15, 2009Health News - BizJournals.com
Seattle Genetics Nabs $60M Upfront From Millennium For “Empowered Antibody”December 15, 2009Xconomy Life Sciences
Genentech scrubs Seattle Genetics dealDecember 11, 2009Health News - BizJournals.com
Genentech sheds $860M Seattle Genetics pact December 11, 2009FierceBiotech
Genentech Ends Collaboration with Seattle Genetics for Phase I Anticancer mAbDecember 11, 2009GEN News Highlights
Roche Scraps Partnership With Seattle Genetics on Lymphoma DrugDecember 11, 2009Xconomy Life Sciences
Seattle Genetics Gets $12M From AgensysNovember 23, 2009Xconomy Life Sciences
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKlinePharma News - Business Wire
Seattle Genetics to Host Conference Call on December 15, 2009, to Discuss Brentuximab Vedotin (SGN-35) PartneringPharma News - Business Wire
Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)Pharma News - Business Wire
Seattle Genetics to Present at 2009 Deutsche Bank Biotech ConfabPharma News - Business Wire
Seattle Genetics Reports Data from Dacetuzumab Phase Ib Combination Clinical TrialsPharma News - Business Wire
Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in LymphomaClinical Trials - Business Wire
Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and ExpositionPharma News - Business Wire



View all the latest news